



Consolidated Financial Statements for the First Quarter Ended June 30, 2020
FY2021 (April 1, 2020 - June 30, 2020) [UNAUDITED]

August 4, 2020

Company name:	Takara Bio Inc.
Stock exchange listings:	Tokyo Stock Exchange (1st section)
Code number:	4974
URL:	http://www.takara-bio.co.jp
Company representative:	Koichi Nakao, President
Contact:	Takuya Kakemi, General Manager of Corporate Management Division, Executive Officer Tel. (077) 565-6970
Scheduled date of quarterly statement filing:	August 12, 2020
Scheduled date of starting delivery of dividends:	—
Supplementary documents of the financial results:	Yes
Financial results information meeting:	No

Notes: 1. The accompanying financial statements have been prepared in accordance with accounting principles and practices generally accepted in Japan.
 2. Amounts are rounded down to the nearest million yen.

1. Results for the three months ended June 30, 2020 (Apr. 1, 2020 – Jun. 30, 2020)

(1) Consolidated operating results

	(Percentages indicate changes from the same period of the previous fiscal year.)			
	Three months ended Jun. 30, 2020		Three months ended Jun. 30, 2019	
	(Millions of yen)	(%)	(Millions of yen)	(%)
Net sales	6,938	(19.8)	8,650	(2.2)
Operating profit	693	(69.2)	2,251	45.8
Ordinary profit	745	(66.1)	2,200	41.1
Net income (loss) attributable to owners of parent	404	(74.6)	1,591	54.2
Net income per share (in yen)	3.36		13.22	
Fully diluted net income per share (in yen)	—		—	
(Note) Comprehensive income	(48)	(—%)	1,778	(—%)

(2) Consolidated financial position

	As of Jun. 30, 2020	As of Mar. 31, 2020
	(Millions of yen)	(Millions of yen)
Total assets	73,593	75,009
Net assets	65,580	66,591
Equity ratio (%)	89.0	88.7
Net assets per share (in yen)	543.82	552.23
(Reference) Equity	65,484	66,496

2. Dividends

	Annual dividends per share in yen		
	Year ended Mar. 31, 2020	Year ending Mar. 31, 2021	Year ending Mar. 31, 2021 (Forecast)
First quarter end	—	—	—
Second quarter end	0.00	—	0.00
Third quarter end	—	—	—
Year end	8.00	—	8.00
Annual	8.00	—	8.00

Note: No revision of dividend payment forecast since the most recently announced payment forecast.

The original disclosure in Japanese was released on August 4, 2020 at 15:00 (GMT+8)

3. Forecast for the year ending March 31, 2021 (Apr. 1, 2020 – Mar. 31, 2021)

(Percentages indicated changes from the same period of the previous fiscal year)

	Six months ending Sep. 30, 2020		Year ending Mar. 31, 2021	
	(Millions yen)	(%)	(Millions yen)	(%)
Net sales	16,870	2.6	39,600	14.6
Operating profit	2,500	(17.6)	6,500	3.6
Ordinary profit	2,559	(13.6)	6,600	4.0
Net income attributable to owners of the parent	1,248	(39.8)	4,000	4.7
Net income per share (in yen)	10.37		33.22	

Note: Revision of financial forecast since the most recently announced payment forecast: Yes.

※ Others

(1) Changes in subsidiaries during the three months ended June 30, 2020

(Changes in specified subsidiaries resulting in change of scope): No

Newly included: – (Name)

Excluded: – (Name)

(2) Application of special accounting methods to the consolidated quarterly financial statements: No

(3) Changes in accounting policies, changes in accounting estimates, and retrospective restatement

1) Changes based on revisions of accounting standard: No

2) Changes other than ones based on revisions of accounting standard: No

3) Changes in accounting estimates: No

4) Restatement: No

(4) Number of outstanding shares (Common stock)

1) Number of outstanding shares at year end (Treasury stocks are included)

As of June 30, 2020 120,415,600

As of March 31, 2020 120,415,600

2) Number of treasury stocks at year end

As of June 30, 2020 –

As of March 31, 2020 –

3) Average number of outstanding shares

As of June 30, 2020 120,415,600

As of June 30, 2019 120,415,600

※ These quarterly financial statements are not subject to auditing.

※ Comment regarding appropriate use of earnings forecasts and other special notes

Forward-looking statements contained in this document are determined by the Takara Bio Company based on information currently available to the Company and include a number of uncertainties. Actual results could differ from these forecasts due to changes in conditions that occur in the future. For information regarding the above, please refer to 1. Qualitative Information for the three months ended June 30, 2020 (4) Qualitative Information Regarding Consolidated Forecasts on page 2 of the attached document.